

MEMORANDUM

TO: All Regional Medical Laboratory Clients

FROM: William Fitter, MD, Chief of Clinical Chemistry department
Mary Pille BS MT (ASCP) SBB, Manager of Chemistry and LCMS

SUBJECT: Fulvestrant cross- reactivity with Estradiol immunoassay

DATE: January 14, 2016

On January 14, 2016, Regional Medical Laboratory received notification from Siemens regarding Fulvestrant cross-reactivity with their Centaur Assay. Their studies have confirmed that samples containing this drug may cross react with the Centaur Estradiol assay. This cross-reactivity could lead to falsely elevated estradiol test results.

Fulvestrant is a drug used in treatment of hormonal receptor-positive recurrent breast cancer in post-menopausal women.

Patients receiving this therapy and monitored using the immunoassay may be falsely elevated and higher values may be reported.

Patients receiving this Fulvestrant drug treatment should be monitored by an assay that has negligible cross reactivity with Fulvestrant such as Estradiol Ultra by Liquid Chromatography-Mass Spectrometry.

RML code:
3600375 ULTR ESTRD Estradiol serum, Ultra

Specimen: serum collected in a **red top no gel** – poured off and frozen.

Going forward, there will be reminder attached to every Estradiol result pertaining to this drug's affect and potential concern.

If you have questions or concerns, please feel free to contact either Dr William Fitter at 918-744-2555, ext 15525, wfitter@sjmc.org or Mary Pille, Manager, Chemistry at 918-744-2555 ext 15788 Mary.Pille@sjmc.org